Effect of flaxseed on systemic inflammation and oxidative stress in diabetic rats with or without chronic kidney disease

PLoS One. 2021 Oct 19;16(10):e0258800. doi: 10.1371/journal.pone.0258800. eCollection 2021.

Abstract

Background: Diabetes mellitus (DM) and chronic kidney disease (CKD) are common causes of morbidity and mortality. Flaxseed contains several bioactive compounds that have been shown to possess anti-inflammatory and antioxidative properties. The aim of the present study was to investigate the possible effect of flaxseed in diabetic rats with adenine-induced CKD.

Methods: Male Wister rats (n = 48) were randomly divided into seven equal groups and treated for 33 consecutive days as follows: G1: control. G2 adenine, G3: streptozotocin (STZ), G4: flaxseed, G5: adenine+flaxseed, G6: STZ+flaxseed, G7: adenine+STZ+flaxseed). DM or CKD were experimentally induced by a single intraperitoneal injection of streptozotocin (STZ) or by adenine via oral gavage, respectively.

Results: Rats fed adenine alone exhibited several changes including decreased body weight, increased food and water intake and urine output, increased urinary albumin/creatinine ratio. They also showed an increase in plasma urea and, creatinine, indoxyl sulfate, neutrophil gelatinase-associated lipocalin and cystatin C, and a decrease in renalase activity. These were associated with significant changes in inflammatory and oxidative biomarkers, e.g., increase in 8-isoprostane, 8 -hydroxy -2-deoxy guanosine and decrease in antioxidant enzymes, as well as increase in interleukins 1β and 6, and NF-κB, and a decrease in interlukin-10. Histopathologically, there was increased tubular necrosis and fibrosis. Concomitant administration of adenine and STZ further worsened the renal damage induced by adenine alone. Flaxseed significantly ameliorated the changes caused by adenine and STZ, given either singly or in combination.

Conclusion: These findings suggest that flaxseed is a potential therapeutic agent in attenuating the progression of CKD in diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / adverse effects
  • Animals
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / pharmacology
  • Biological Factors / administration & dosage*
  • Biological Factors / pharmacology
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / drug therapy*
  • Disease Models, Animal
  • Flax / chemistry*
  • Interleukin-10 / metabolism
  • Interleukin-1beta / metabolism
  • Interleukin-6 / metabolism
  • Male
  • NF-kappa B / metabolism
  • Oxidative Stress / drug effects
  • Random Allocation
  • Rats
  • Rats, Wistar
  • Renal Insufficiency, Chronic / chemically induced
  • Renal Insufficiency, Chronic / drug therapy*
  • Seeds / chemistry*
  • Streptozocin / adverse effects
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Biological Factors
  • IL1B protein, rat
  • Il6 protein, rat
  • Interleukin-1beta
  • Interleukin-6
  • NF-kappa B
  • Interleukin-10
  • Streptozocin
  • Adenine

Grants and funding

This work was supported by funds from the Ministry of Higher Education, Research and Innovation (RC/MED/PHAR/19/01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.